- Home
- RVSN vs CMMB Comparison
RVSN vs CMMB Comparison
Compare RVSN & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RVSN | CMMB |
|---|---|---|
| Founded | 2016 | 2004 |
| Country | Israel | Israel |
| Employees | 47 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0M | 11.1M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | RVSN | CMMB |
|---|---|---|
| Price | $4.33 | $1.39 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | 11.7K | ★ 222.8K |
| Earning Date | 03-31-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 101.67 |
| EPS | N/A | ★ 0.04 |
| Revenue | N/A | N/A |
| Revenue This Year | $860.32 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $35.00 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.17 | $0.87 |
| 52 Week High | $9.39 | $3.86 |
Technical Indicators
Market Signals| Indicator | RVSN | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Price Performance
Historical ComparisonAbout RVSN Rail Vision Ltd.
Rail Vision Ltd is an early commercialization stage technology company focused on railway safety systems using AI-integrated sensing systems. The company develops and commercializes proprietary, multi-spectral electro-optic platforms that provide extended-range situational awareness and real-time hazard detection. Using machine learning algorithms to identify and classify obstacles, the company's technology enhances safety, improves operational efficiency, and supports continuity across deployments.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.